Exchange: NASDAQ·Updated 05:34 PM EDT
TSHA logo

TSHA Taysha Gene Therapies Inc

$4.49
$0.06
(1.35%)
Today
Closed $4.49
$0.00
(0.00%)
After Hours
EarningsNov 4
Mkt Cap$1.44B
Vol5.38M

About TSHA

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
61

Bullish Sentiment

How do you feel about TSHA?

ValueBioTracker
$TSHA I’m in. Just the U.S. backlog is around 6000-8000 patients. Net price would be at least $2M per patient. We’re talking about $12B-$16B just from the backlog, not even talking about new patients or ex-U.S. patients
6
King_of_Bio
$TSHA If you know the future of this company - you'd be thanking God for this drop. I'm ten toes down for this stock. Period.
6
Mydogbruno69
$TSHA hasn’t been under 5 is a long time wow. Guess a good place to add or get in if you’re not already
4
Jhane13
$TSHA See you at 17. The rest trying to keep this down or act like selling, f your mother.
3
warren5677
$TSHA this action the last month is pure BS. Then today were up close to 10% with the XBI flying and now damn near flat.
2
Dark_Horse_Investments
$TSHA Rather horrific action the last ~two months. We sit tight, brace, ride the turbulence beyond the “stunod” political calendar & its political parasites, and let the data mature as we inch closer to BLA readiness. TSHA 102 efficacy is already baked in; patients improve, consistently & unequivocally. Considering the macro setup, excessive debt issuance (public & corporate) crowding out equities & adding systemic risk, how do these factors affect TSHA’s ultimate outcome? Past performance is not indicative of future performance: not convinced TSHA will replicate the ~$8.7B exit achieved by Nolan/Suku’s prior company, even with a similar patient population footprint. 1) Is anyone concerned that buyout probability is diminishing? 2) Could TSHA follow a path similar to $RARE, approved products, real revenue, but a market cap capped near ~$2B? Welcome substantive thoughts.
1
PLATINUM_TRADES
$TSHA I told u yesterday where it was going another overnight swing winner.... why aren't u in the Pitt again? 🚨🚨
Xit4profit
$TSHA I literally almost sold all of my 20,000 shares of this stock today. I've been in it for quite some time. It's been a roller coaster. It's been a wait-and-see wait-and-see then it bumps and it goes back down. Anyway, I think I'm gonna sell half when it gets back to the five mark and then let it ride. A Little concerned. About future...

Advertisement|Remove ads.